详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases.

64| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China [2]Advanced Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China [3]Department of China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing, China [4]Department of Neurosurgery, Wayne State University School of Medicine, Detroit, Michigan, USA

出处：

DOI：

ISSN：

关键词： ezetimibe statin atherosclerotic vascular disease

摘要：

It is well known that atherosclerotic vascular disease (ASVD) in the elderly is a global disease with high morbidity, mortality and disability, and plasma LDL-C correction is the most important strategy for ASVD control. However, a large proportion of patients failed to achieve their ideal LDL-C goals after statins use. Ezetimibe, a newly non-statin lipid-lowering agent, is an inhibitor of exogenous cholesterol absorption. Whereby, ezetimibe plus statins may reduce LDL-C more strongly than statins alone. Differed from any other papers published previously, which only involved ezetimibe plus statins for coronary heart disease, the highlight of this paper is to summarize the efficacy and safety of ezetimibe plus statins in all kinds of ASVD subtypes and their related diseases, mainly included aortic atherosclerosis, coronary artery disease, cerebrovascular and peripheral artery diseases. Obviously, this paper is inimitable, which will provide the readers an important reference, especially in treating the elderly with multi-organs atherosclerosis.Copyright: © 2021 Wan et al.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 2 区医学

小类 | 2 区老年医学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区老年医学

JCR分区：

出版当年[2019]版：

Q1 GERIATRICS & GERONTOLOGY

最新[2023]版：

Q1 GERIATRICS & GERONTOLOGY

影响因子： 7 最新[2023版] 7.1 最新五年平均 5.402 出版当年[2019版] 5.506 出版当年五年平均 4.232 出版前一年[2018版] 6.745 出版后一年[2020版]

第一作者：

第一作者机构： [1]Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China [2]Advanced Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China [3]Department of China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing, China

通讯作者：

通讯机构： [1]Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China [2]Advanced Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China [3]Department of China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing, China [*1]Xuanwu Hospital, Capital Medical University, Beijing, 100053, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]不同降脂方案治疗他汀不耐受冠状动脉粥样硬化性心脏病患者的效果分析 [2]Understanding Drug Interactions in Antiplatelet Therapy for Atherosclerotic Vascular Disease: A Systematic Review [3]动脉粥样硬化性下肢动脉病变血管超声评估进展及相关影响因素 [4]Characterization of the unique Chinese W483X mutation in the low-density lipoprotein-receptor gene in young patients with homozygous familial hypercholesterolemia [5]阿托伐他汀钙联合依折麦布用于急性冠状动脉综合征的效果分析 [6]Rosuvastatin combined with ezetimibe decreases myocardial injury in acute coronary syndrome patients receiving percutaneous coronary intervention [7]Statin for Neuroprotection in Spontaneous Intracerebral Hemorrhage (STATIC) [8]Effect of pioglitazone on inflammation and calcification in atherosclerotic rabbits: An [9]老年缺血性卒中住院患者他汀药物治疗短期预后及不良反应相关性研究 [10]Inpatient statin use and stroke recurrence in patients with or without diabetes mellitus.

日	一	二	三	四	五	六

今天

清空